- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06888687
제 2 형 당뇨병 환자의 지속적인 포도당 모니터링 유무에 관계없이식이 요법 지원의 비교. (CARE-T2D)
지속적인 포도당 모니터링 지원 원격 전자 건강식이 요법 2 형 당뇨병 환자에게 힘을 실어줍니다.
A parallel, single-blinded, randomised clinical trial conducted remotely across Australia from the Mary MacKillop Institute for Health Research (MMIHR, Australian Catholic University) for individuals with type 2 diabetes, by researchers from Australian Catholic University, University of Adelaide, University of Queensland, University of Wollongong, Monash University, Monash Partners, Deakin University, La Trobe University and Melbourne University.
연구 개요
상태
상세 설명
In a parallel groups design, a total of 156 individuals will be recruited. After baseline pathology (HbA1c), blinded (Libre Pro iQ) continuous glucose monitoring (CGM) data and questionnaires (via REDCap) have been collected, participants will be randomised into one of two groups (DIET, dietetic support only; CGMD, CGM plus dietetic support). All participants will receive four (4) dietetic consults via telehealth at weeks 2, 6, 10 and 16, the content of which will be related to the randomised condition. Measurements will be repeated at 3 and 6 months from baseline to assess the changes in primary and secondary outcomes.
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Victoria
-
Melbourne, Victoria, 호주, 3065
- Australian Catholic University
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Aged 18+ years
- Reside anywhere in Australia and have a postal address
- Confirmed T2D diagnosis by a GP/endocrinologist
- Current HbA1c of ≥7.0%
- Have a smartphone and able to independently use it
Exclusion Criteria:
- Under the age of 18 years
- Use of insulin therapy (within the last three months) or medications which interfere with blood glucose levels (i.e. steroids)
- Use of CGM within the last six months
- Eating Disorder Examination Questionnaire (EDE-Q) global score >2.8 OR global score > or equal to 1.52, with sum of Q14-18 > or equal to 4
- Currently having ongoing consultations with an APD or have had a consult with an APD (within last three months)
- Not weight stable (>5 kg change over last three months)
- Severe hypoglycaemic event (i.e. requiring assistance) within last six months
- Change of antihyperglcyaemic medications within last three months
- Women who are pregnant or breastfeeding (within 24 weeks)
- History of psychotic disorder, or current diagnosis of other major psychiatric illness (e.g. mood disorder, eating disorder, substance use disorder)
- History of blood disorders (including but, not limited to, anemia and thalassemia) that impact the primary outcome (HbA1c)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Dietetic support only
This group is designed to act as a comparator using 'standard care' in dietetics practice. Dietary advice provided to this participant group will be performed by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. |
Dietary advice will be provided by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. |
|
실험적: CGM plus dietetic support
The CGM plus dietetic support group will be provided 'standard care' dietetic support alongside the use, and interpretation of, the CGM data collected to assist in the understanding of dietary modifications on glucose management. As per the DIET group, dietary advice provided to this participant group will be performed by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. The CGM data collected via LibreLink will be used by both the participant and the dietitian to inform dietary modifications. |
Dietary advice will be provided by Accredited Practicing Dietitians (APDs) in line with evidence-based guidelines, specifically the T2DM best-practice guidelines plus Australian Dietary Guidelines (i.e. Australian Guide to Healthy Eating) to improve diet quality, and strategies to promote adherence. Abbott FreeStyle Libre 2+ CGM sensors will be used to provide feedback on interstitial glucose concentrations over 15 day periods per sensor. Nine sensors will be provided for the 6-month period, for 3 months of continuous use and 3 months of intermittent (2 weeks on - 2 weeks off) use. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
HbA1c
기간: baseline, 6 months
|
Glycated haemoglobin concentration |
baseline, 6 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
HbA1c
기간: 3 months
|
Glycated haemoglobin concentration |
3 months
|
|
24 h assessment of glycaemia
기간: baseline, 6 months
|
24 h glucose measures assessed by blinded CGM (including, but not limited to, time in range, CV) |
baseline, 6 months
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
CGM application and use
기간: From 0 to 26 weeks, per 2 week period of sensor use
|
number of days of CGM use and interaction with viewing CGM data (via LibreLink); CGMD group ony |
From 0 to 26 weeks, per 2 week period of sensor use
|
|
Per protocol analysis
기간: 6 months
|
Primary analysis of the primary outcome (0-6 months HbA1c) is going to be intention to treat. Therefore, secondary analysis of all other variables will be a per-protocol (PP) analysis. Inclusion in PP analysis will be defined by: 1. Attendance at ≥3 dietetic consults, within ±10 days of the designated 2-, 6-, 10- and 16-week time points. |
6 months
|
|
Dietary intake
기간: baseline, 3 months, 6 months
|
energy and macronutrient composition calculated from food records |
baseline, 3 months, 6 months
|
|
Fasting blood glucose
기간: baseline, 3 months, 6 months
|
fasting blood glucose concentrations |
baseline, 3 months, 6 months
|
|
Adherence
기간: baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 18 weeks, 20 weeks, 26 weeks
|
measures of adherence assessed by self-report (questionnaire) |
baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 18 weeks, 20 weeks, 26 weeks
|
|
hs-CRP
기간: baseline, 3 months, 6 months
|
fasting high sensitive C-Peptide concentrations |
baseline, 3 months, 6 months
|
|
Fasting cholesterol
기간: baseline, 3 months, 6 months
|
Fasting cholesterol concentrations (total, HDL and LDL) |
baseline, 3 months, 6 months
|
|
Fasting lipid concentration
기간: baseline, 3 months, 6 months
|
fasting triglyceride concentrations |
baseline, 3 months, 6 months
|
|
Medication effect score (MES)
기간: baseline, 6 months
|
Medication effect score for antihyperglycemic medications |
baseline, 6 months
|
|
Participant experience
기간: 6 months
|
Qualitative semi-structured interviews |
6 months
|
|
Physical activity
기간: baseline, 3 months, 6 months
|
Self-reported questionnaire (International Physical Activity Questionnaire (IPAQ) - Long Form) |
baseline, 3 months, 6 months
|
|
Sleep quality and quantity
기간: baseline, 3 months, 6 months
|
Self-reported questionnaire (Pittsburgh Sleep Quality Index (PSQI)) |
baseline, 3 months, 6 months
|
|
Eating behaviours
기간: baseline, 3 months, 6 months
|
Self-reported questionnaire (Eating Disorders Examination Questionnaire (EDEQ)) |
baseline, 3 months, 6 months
|
|
Health literacy
기간: baseline, 3 months, 6 months
|
self-reported questionnaire (Health Literacy Questionnaire (HLQ)) |
baseline, 3 months, 6 months
|
|
Dietary quality
기간: baseline, 3 months, 6 months
|
Assessed using the Healthy Eating Index For Australian adults (HEIFA) |
baseline, 3 months, 6 months
|
|
Diabetes self-management
기간: baseline, 3 months, 6 months
|
Self-reported questionnaire (Diabetes Self-Management Questionnaire (DSMQ-R)) |
baseline, 3 months, 6 months
|
|
Diabetes distress
기간: baseline, 3 months, 6 months
|
Self-reported questionnaire (Type 2 Diabetes Distress Assessment Scale (T2DDAS)) |
baseline, 3 months, 6 months
|
|
Overall well-being
기간: baseline, 3 months, 6 months
|
Self-reported questionnaire (WHO-5) |
baseline, 3 months, 6 months
|
|
Diabetes-specific well-being
기간: baseline, 3 months, 6 months
|
Self-reported questionnaire (DAWN Impact of Diabetes Profile (DIDP-7)) |
baseline, 3 months, 6 months
|
|
Treatment satisfaction
기간: baseline, 3 months, 6 months
|
self-reported questionnaire (Diabetes Treatment Satisfaction Questionnaire (DTSQs (status) and DTSQc (change))) |
baseline, 3 months, 6 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- 2024-3690HC
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The data that support the findings of this study will be available from the corresponding author for a period of 36 months from publication, upon reasonable request for academic use. The data will not be made publicly available, as it contains information that could compromise research participant consent.
IPD 공유 액세스 기준
Reasonable requests of data for academic use will be considered. Requests can be made to the corresponding author of the publication. Data will not be made publicly available as it contains information that could compromise research participant consent.
IPD 공유 지원 정보 유형
- 연구_프로토콜
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .